<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311882</url>
  </required_header>
  <id_info>
    <org_study_id>4305-035</org_study_id>
    <nct_id>NCT01311882</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate Next Day Effects of MK-4305 on Driving Performance in Healthy Non-Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate next-day residual effects of MK-4305 on highway driving
      performance in healthy, non-elderly participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean differences of standard deviation of lateral position (SDLP) on highway driving between MK-4305 and placebo</measure>
    <time_frame>Day 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean differences of standard deviation of lateral position (SDLP) on highway driving between zopiclone and placebo</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean differences of standard deviation of lateral position (SDLP) on highway driving between MK-4305 and placebo</measure>
    <time_frame>Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean differences of standard deviation of lateral position (SDLP) on highway driving between zopiclone and placebo</measure>
    <time_frame>Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean standard deviation of speed (SDS) on highway driving (MK-4305 versus placebo)</measure>
    <time_frame>Day 2 and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Word learning test (MK-4305 versus placebo)</measure>
    <time_frame>Day 2 and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body sway area: Area of the 95% confidence ellipse enclosing the center of pressure (A95) (MK-4305 versus placebo)</measure>
    <time_frame>Day 2 and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 14 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants discontinued from study due to adverse events</measure>
    <time_frame>Up to 14 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>MK-4305 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 and Day 8- 4 x 10 mg MK-4305 and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4305 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 and Day 8- 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zopiclone 7.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1 and Day 8- 1 x 7.5 mg zopiclone and 4 x 10 mg MK-4305 matching placebo; Days 2-7- 4 x 10 mg MK-4305 matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Day 1 and Day 8- 4 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305 matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-4305 40 mg</intervention_name>
    <description>4 x 10 mg MK-4305 tablets</description>
    <arm_group_label>MK-4305 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-4305 20 mg</intervention_name>
    <description>2 x 10 mg MK-4305 tablets</description>
    <arm_group_label>MK-4305 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zopiclone</intervention_name>
    <description>1 x 7.5 mg Zopiclone tablet</description>
    <arm_group_label>Zopiclone 7.5 mg</arm_group_label>
    <other_name>Zimovane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grossly Matching Placebo for Zopiclone</intervention_name>
    <description>Grossly Matching Placebo for Zopiclone</description>
    <arm_group_label>MK-4305 40 mg</arm_group_label>
    <arm_group_label>MK-4305 20 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for MK-4305</intervention_name>
    <description>Matching Placebo for MK-4305</description>
    <arm_group_label>MK-4305 20 mg</arm_group_label>
    <arm_group_label>Zopiclone 7.5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female participants of reproductive potential must agree to use (and/or have their
             partner use) acceptable methods of birth control beginning at least 2 weeks prior to
             the administration of the first dose of study drug throughout the study

          -  Has a body mass index (BMI) within the range of 18 to 30 kg/m^2

          -  Possesses a valid driver's license for 3 years or more with at least 5000 km/year on
             average within the last 3 years

          -  Is capable of driving a manual transmission vehicle and is willing to drive on a
             highway

          -  Is judged to be in good health

          -  Has a regular sleep pattern

          -  Is not visually impaired

        Exclusion Criteria:

          -  Has a history of a persistent sleep abnormality

          -  Has neurological disease/cognitive impairment

          -  Has a history of cataplexy

          -  Is a regular user of sedative-hypnotic agents

          -  Is allergic to zopiclone

          -  Has traveled across 3 or more time zones (transmeridian travel) in the last 2 weeks
             prior to study start and will travel across 3 or more time zones throughout study
             duration

          -  Works a night shift and is not able to avoid night shift work within 1 week before
             each treatment visit

          -  Is pregnant or nursing

          -  Does not qualify as a proficient driver according to the driving instructors
             evaluation of subject's driving on the driving test practice session
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme B.V.</name>
      <address>
        <city>Haarlem</city>
        <zip>2031 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers. Sleep. 2015 Nov 1;38(11):1803-13. doi: 10.5665/sleep.5168.</citation>
    <PMID>26039969</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zopiclone</mesh_term>
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

